Anteris Technologies

Historical price data

Anteris Technologies is a clinical-stage medical device company focused on developing superior solutions for structural heart disease, with a primary emphasis on aortic stenosis. Its core innovation is the DurAVR™ transcatheter heart valve system, engineered to mimic the native aortic valve's anatomy and function, aiming to overcome limitations of current TAVR devices related to hemodynamics and long-term durability. The company is publicly listed on the Australian Securities Exchange (ASX: AVR) and is progressing its pivotal clinical program to validate the DurAVR™ system's performance. Anteris's mission is to set a new standard in heart valve therapy by delivering a valve that performs like a patient's own.

Biomimetic engineering platform for designing single-piece, polymer-based transcatheter heart valves that replicate the anatomy and hemodynamic function of the native human aortic valve.

Total raised: $45M

Anteris competes in the TAVR market dominated by Edwards Lifesciences and Medtronic. Its differentiation is based on its biomimetic, single-piece polymer valve design, which aims to provide superior hemodynamics (blood flow) and enhanced durability compared to current assembled tissue-based valves. Clinical validation of these claims is critical to its competitive success.